Clinical trials: Immune System Disorder (Healthy Volunteer)
Asthma, Healthy Subjects or Volunteers
A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
- Trial name
- NCT02085473
- Testing
- Tralokinumab 300 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Hepatitis B
Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine
In this study, subjects who received primary neonatal vaccination with hepatitis B vaccine at 0, 1, 2, 12 months, 20 years ago in the 103860/272 primary study will be evaluated for immunological memory to hepatitis B vaccine via…
- Trial name
- NCT00657657
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
HIV Infections
Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of multiantigen HIV (HIV-MAG) plasmid DNA (pDNA) vaccine co-administered with recombinant human IL-12 pDNA (GENEVAX® IL-12) followed or preceded…
- Trial name
- NCT01496989
- Testing
- HIV-MAG (3,000mcg), GENEVAX® IL-12 (100mcg), GENEVAX® IL-12 (1000mcg)
- Where
- 3 sites in Kenya, Rwanda and 1 more
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
- Trial name
- NCT00061243
- Testing
- HIV-1 DNA vaccine with protein vaccine boost
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatic Insufficiency
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of single oral doses of Alisporivir in subjects with mild and moderate hepatic impairment compared to matched healthy subjects with normal…
- Trial name
- NCT01860326
- Testing
- Alisporivir
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA
Diabetes Mellitus, Diabetes Mellitus, Type 1
Pharmacokinetics Study of Gamma-aminobutyric Acid
The purpose of this study is to determine upon administering GABA orally to a person how it is absorbed, distributed, as well as the drug's pharmacological effects on the body such as glucose levels, serum C-peptide and/or…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- GABA-PK (NCT01917760)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.
Hereditary Angioedema, Healthy Volunteers
Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population
In emergency room, this is crucial to diagnose an acute attack of hereditary angioedema (HAE) to quickly provide the efficient treatment.
- Trial name
- BRADYKID (NCT02854397)
- Testing
- blood sample
- Where
- 14 sites in France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erythematosus
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects.
- Trial name
- NCT06657703
- Testing
- HC022
- Where
- 3 sites in China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HC Biopharma Inc.
Healthy Volunteers
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
- Trial name
- NCT07248865
- Testing
- CLYM116
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Climb Bio, Inc.
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Food Allergy
Prevalence of Food Allergies to Proteins From Different Legumes
The objective of the study is to assess the prevalence of a sensitization to proteins from legumes by skin prick test using commercial extracts (peanut, soy, and pea) and raw material (lupin) in atopic and healthy subjects.
- Trial name
- NCT01728168
- Where
- Germany
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- University of Jena
HIV Infections
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
To evaluate the safety and immunogenicity of live recombinant canarypox ALVAC-HIV vCP205 in combination with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) at 80 microg and 250 microg.
- Trial name
- NCT00001090
- Testing
- APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
- Where
- 4 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Esophagitis
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral…
- Trial name
- NCT07093008
- Testing
- AQ280 Capsule, AQ280 Tablet for Oral Suspension
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Asthma
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers.
- Trial name
- NCT03441815
- Testing
- XC8
- Where
- Russia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Pulmonary Disease, Chronic Obstructive, Asthma
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled…
- Trial name
- NCT01176747
- Testing
- BDP/formoterol NEXT DPI
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Chronic Obstructive Pulmonary Disease
Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers
The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that daily magnesium supplement will benefit patients with asthma and chronic…
- Trial name
- NCT01113138
- Testing
- Mablet (Magnesium-supplement), Magnesium Sulfate
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Asthma
Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes
This study is the first administration of GSK2292767 to humans. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat inhaled doses of GSK2292767 in healthy…
- Trial name
- NCT03045887
- Testing
- GSK2292767 50 μg, GSK2292767 500 μg
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Neutralizing Interleukin (IL)-6
The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of…
- Trial name
- NCT07493317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.